News
NNVC
1.140
-2.56%
-0.030
NanoViricides reports Q3 results
Seeking Alpha · 4d ago
Weekly Report: what happened at NNVC last week (1109-1113)?
Weekly Report · 5d ago
NanoViricides Advances NV-387 Measles Treatment Toward Clinical Trials Amid Rising Global Outbreaks
Benzinga · 11/10 13:47
Weekly Report: what happened at NNVC last week (1102-1106)?
Weekly Report · 11/09 10:25
'US Measles Cases Top 5,000 for the First Time Since the 1990s' - Bloomberg
Benzinga · 11/06 15:31
Weekly Report: what happened at NNVC last week (1026-1030)?
Weekly Report · 11/02 10:25
NanoViricides says Phase IIa trial of NV-387 in ebola ‘progressing well’
TipRanks · 10/27 13:20
'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberg
Benzinga · 10/27 12:39
As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides
Barchart · 10/27 08:15
Weekly Report: what happened at NNVC last week (1019-1023)?
Weekly Report · 10/26 10:25
NanoViricides Files Prospectus For Offering $2.375M Common Stock
Benzinga · 10/21 14:26
NanoViricides says NV-387 demonstrates ‘strong’ parameters in animal model study
TipRanks · 10/20 12:51
NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups
Benzinga · 10/20 12:47
Weekly Report: what happened at NNVC last week (1012-1016)?
Weekly Report · 10/19 10:25
NanoViricides announces Phase IIA Ebola trial of NV-387 is progressing well
TipRanks · 10/13 13:01
NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well
Benzinga · 10/13 12:48
Weekly Report: what happened at NNVC last week (1005-1009)?
Weekly Report · 10/12 10:31
NanoViricides says Phase II trial of NV-387 in ebola ‘proceeding as designed’
TipRanks · 10/05 12:50
NanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early Enrollment
Benzinga · 10/05 12:49
Weekly Report: what happened at NNVC last week (0928-1002)?
Weekly Report · 10/05 10:30
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.